DGAP-News: APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed new CFO

APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed CFO

Monheim am Rhein, 16 December 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, strengthens its management for future growth and appoints Thomas Zimmermann as Chief Financial Officer (CFO). Mr. Zimmermann will join the management team led by Chief Executive Officer (CEO) Karlheinz Gast and Chief Product Officer (CPO) Thomas Milz as of 1 January 2022. As CFO, Thomas Zimmermann will assume responsibility for Finance, Supply Chain, and IT.

Thomas Zimmermann has around 25 years of experience in responsible positions with a focus on finance in the pharmaceutical industry. Most recently, he worked in Germany and Austria as Finance Director for the Swiss pharmaceutical company Galderma and as a tax advisor syndic. The business graduate (Diplom-Kaufmann) began his professional career at Ernst & Young as a certified public auditor and certified tax advisor and subsequently in the Transaction Advisory Services division.

"With Thomas Zimmermann, we are gaining a proven expert in the pharmaceutical industry and an experienced financial manager in the areas of Finance, Tax, and Controlling as well as Supply Chain and Internal Control. This, together with his extensive network, makes him the ideal candidate for the planned further development of our company. As 'The Single Pill Company', we combine active ingredients in one preparation for a more improved therapy result. This is the approach we are also pursuing with regard to our corporate structures. By bundling management competencies, APONTIS PHARMA is excellently positioned for future growth," says Karlheinz Gast, Chief Executive Officer (CEO) of APONTIS PHARMA AG.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia, and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical regions. From here, the Company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
[email protected]
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
[email protected]
T: +49 89 125 09 0330